Cardio Diagnostics director granted 2,854 stock options

Cardio Diagnostics Holdings, Inc. director Peter K. Fung received a grant of stock options as part of his compensation.

Rhea-AI Filing Summary

Cardio Diagnostics Holdings, Inc. director Peter K. Fung received a grant of stock options as part of his compensation. On June 30, 2026, he was awarded 2,854 stock options with a conversion price of $2.19 per share, each option representing the right to buy one share of common stock. These are classified as a grant or award, not an open-market purchase or sale. Following this award, Fung holds a total of 12,367 stock options linked to Cardio Diagnostics common stock, giving him additional potential future ownership if he chooses to exercise the options before they expire in 2036.

Insider Trade Summary

Grant/Award: 2,854 shares

Grant/Award 1 txn

Insider Fung Peter K

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	2,854	$2.19	$6K

Holdings After Transaction: Stock Options (Right to Buy) — 12,367 contracts (Direct)

Key Figures

Options granted: 2,854 options Exercise price: $2.19 per share Total options after grant: 12,367 options +1 more

4 metrics

Options granted 2,854 options Stock options award on June 30, 2026

Exercise price $2.19 per share Conversion or exercise price for granted options

Total options after grant 12,367 options Total stock options held following this transaction

Option expiration June 30, 2036 Expiration date of the granted stock options

Key Terms

Stock Options (Right to Buy), Grant, award, or other acquisition, Common Stock

3 terms

Stock Options (Right to Buy) financial

"security_title: Stock Options (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cardio Diagnostics (CDIO) director Peter K. Fung report in this Form 4?

Peter K. Fung reported receiving a grant of 2,854 stock options for Cardio Diagnostics common stock. This is a compensation-related award, not a market trade, and increases his potential future ownership if he exercises the options.

How many Cardio Diagnostics (CDIO) stock options did Peter K. Fung receive and at what price?

Peter K. Fung received 2,854 stock options with a conversion or exercise price of $2.19 per share. Each option represents the right to buy one share of Cardio Diagnostics common stock at that price in the future.

What is Peter K. Fung’s total option position in Cardio Diagnostics (CDIO) after this grant?

After the grant, Peter K. Fung holds 12,367 stock options in total. This total includes the newly awarded 2,854 options and represents his potential future right to acquire Cardio Diagnostics common shares through option exercise.

Is the Cardio Diagnostics (CDIO) Form 4 for Peter K. Fung a stock purchase or sale?

The Form 4 reflects a grant or award acquisition of stock options, coded as transaction type “A.” It is not an open-market buy or sell of shares, but a compensation-related option award from the company.

When do Peter K. Fung’s new Cardio Diagnostics (CDIO) stock options expire?

The newly granted 2,854 stock options for Cardio Diagnostics common stock have an expiration date of June 30, 2036. Fung may choose to exercise these options before that date at the fixed price of $2.19 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 12:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fung Peter K

(Last) (First) (Middle)

311 W. SUPERIOR ST., SUITE 444

C/O CARDIO DIAGNOSTICS HOLDINGS, INC.

(Street)

CHICAGO ILLINOIS 60654

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cardio Diagnostics Holdings, Inc. [ CDIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$2.19	06/30/2026		A		2,854		06/30/2026	06/30/2036	Common Stock	2,854	$2.19	12,367	D

Explanation of Responses:

	/s/Elisa Luqman as attorney-in-fact for Peter Fung	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)